Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals including any health technology assessment-related or other policy discussions that might involve Health Canada and its ongoing relationship with Canada's Drug Agency and/or other pan-Canadian health organizations.Read more
Engagement with officials on issues related to the National Strategy for Rare Disease Drugs, and other policies or programs related to rare diseases.
Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Justine Frame · Policy Advisor, Health Canada (HC)
Engagement with officials on issues related to the National Strategy for Rare Disease Drugs, and other policies or programs related to rare diseases.Read more
Innovation, Science and Economic Development Canada regarding the Innovation and Skills Agenda, the Biomanufacturing and Life Sciences Strategy and other government policies and programs related to incenting research and development activities in Canada.
Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board
Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals including any health technology assessment-related or other policy discussions that might involve Health Canada and its ongoing relationship with Canada's Drug Agency and/or other pan-Canadian health organizations.
Daniel MacDonald · Director General, Office of Pharmaceutical Management Strategies, Health Canada (HC)
Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals including any health technology assessment-related or other policy discussions that might involve Health Canada and its ongoing relationship with Canada's Drug Agency and/or other pan-Canadian health organizations.Read more
National pharmacare, with a particular focus on access to medicines and rare disease and orphan drug policies
Engagement with officials on issues related to the National Strategy for Rare Disease Drugs, and other policies or programs related to rare diseases.
Daniel MacDonald · Director General, Health Canada (HC)
Engagement with officials on issues related to the National Strategy for Rare Disease Drugs, and other policies or programs related to rare diseases.Read more
Bill C-64: An Act respecting pharmacare, with a particular focus on access to medicines and rare disease and orphan drug policies
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026.
Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month.
Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means.
Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence.
PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.